Literature DB >> 11322011

[Prescriptions and consumption of hypnotic and anxiolytic drugs in the South University Hospital of Marseille].

P Villani1, C Morciano, P Ambrosi, R Brondino-Riquier, P Bertault-Peres, C Penot-Ragon, G Bouvenot.   

Abstract

An investigation of prescription and consumption of hypnotic and anxiolytic drugs in hospital was carried out and has associated a transverse prescription study and a prospective consumption study. The prescription study was undertaken on one day in several medical departments of Sainte-Marguerite Hospital in Marseille in February 1999. Of the 91 hospitalized patients included, 42 (46 per cent) had been prescribed a hypnotic or anxiolytic. Furthermore, the quantities of drugs taken out of the pharmacy during the month of February were 1.54 time more than those prescribed. This discrepancy was even more obvious in the case of certain benzodiazepines such as bromazepam (ratio from 1 to 4) and lorazepam (ratio from 1 to 8). Self-prescription and patients being supplied without a prescription are the hypotheses advanced to explain this phenomenon.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11322011

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  3 in total

1.  Does hospitalisation affect hypnotic and anxiolytic drug prescribing?

Authors:  Philippe Fagnoni; Samuel Limat; Emmanuel Haffen; Thierry Henon; Micheline Jacquet; Daniel Sechter; Marie Christine Woronoff-Lemsi
Journal:  Pharm World Sci       Date:  2007-03-17

2.  [The impact of the COVID-19 pandemic on first-line primary care in southeastern France: Feedback on the implementation of a real-time monitoring system based on regional health insurance data].

Authors:  B Davin-Casalena; M Jardin; H Guerrera; H Tréhard; D Lapalus; C Ménager; S Nauleau; V Cassaro; P Verger; V Guagliardo
Journal:  Rev Epidemiol Sante Publique       Date:  2021-04-27       Impact factor: 1.019

3. 

Authors:  B Davin-Casalena; M Jardin; H Guerrera; J Mabille; H Tréhard; D Lapalus; C Ménager; S Nauleau; V Cassaro; P Verger; V Guagliardo
Journal:  Rev Epidemiol Sante Publique       Date:  2021-08-10       Impact factor: 1.019

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.